with motor neurone disease or bulbar palsy. support the use of nebulised drugs in the from the supine position then administration of 
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drugs by this route is impractical and probably There is increasing anecdotal evidence to support their use in patients with breathlessness inappropriate.
Nebulisers are being used increasingly in related to cancer, 1 and it has been suggested that patients with lymphangitis are most likely palliative care settings which do not have the infrastructure for a nebuliser service. Some to derive benefit. However, a recent randomised placebo controlled trial failed to show practical considerations can be overlooked. The following are essential: education of patients a significant effect, although some patients may benefit.
10 and carers; instruction on cleaning of equipment including "disposables"; a system that Various opioid drugs have been used 11 of which morphine and diamorphine are the most ensures regular maintenance and electrical safety of equipment; and arrangements for col-common; fentanyl may be associated with less bronchospasm. 1 Morphine 6-glucuronide, codlection of the equipment after a patient's death. Doctors who prescribe nebuliser treatment at eine and hydromorphone have also been used.
None of these drugs is licensed for adhome or in hospices should consider collaborating with their local nebuliser service on ministration by nebuliser in the UK.
For all these drugs there is no consensus on these issues.
the most appropriate starting dose or schedule, the best steps for dose titration, or on the optimal design and length of a therapeutic trial.
Drugs used
It is usually assumed that equianalgesic doses The drugs most commonly used in this setting of different opioids will have similar effects on are described in table 1. Since the use of nebuthe symptom of breathlessness, but there is no lised local anaesthetics and nebulised opioids scientific evidence to support this premise. is largely peculiar to palliative care, these in-
The pharmacokinetics of nebulised opioids terventions are discussed in more detail below.
have been investigated. 12 13 There is some evidence that the bioavailability of nebulised morphine in normal volunteers is very low (<5%)    relative to the intravenous route. 14 It is, howOne study showed a ventilatory stimulant effect ever, dangerous to assume that this is always in normal volunteers 2 but studies to date do the case because the systemic bioavailability not support the use of nebulised local an-of any nebulised drug can vary considerably aesthetics for breathlessness in patients with depending on the equipment used and the chronic obstructive pulmonary disease degree of inspiratory effort of which the patient (COPD). 3 4 In a recent randomised study of is capable. Thus, the simultaneous use of both palliative care, patients with cancer showed no nebulised and oral or subcutaneous opioids benefit from nebulised lignocaine compared may carry a risk of cumulative toxicity prowith normal saline. 5 The only study to in-portional to the dose of nebulised opioid advestigate the efficacy of local anaesthetics in ministered. the treatment of cough showed encouraging Nebulised opioids are unlikely to have a place results 6 and there are unpublished anecdotal in the management of pain and, in any case, reports of its use in patients with cough of the oral, rectal and subcutaneous routes are various causes (table 1) . A dose of nebulised more appropriate. There is a risk of broncholocal anaesthetic before retiring at night can be spasm, particularly with higher doses. The first very helpful in reducing cough stimulated by dose should always be administered in a supooling of saliva in the hypopharynx of patients pervised setting where medical or nursing interwith motor neurone disease or multiple sclero-vention is available in case of bronchospasm sis but may increase the risk of aspiration. The or other adverse effect. Some, but not all, relative merits of lignocaine and bupivacaine clinicians use preservative-free opioid prehave not been assessed. The reduced sensitivity parations in an attempt to reduce the risk of of the cough reflex means that patients should bronchospasm. If morphine is employed then fast for one hour after treatment with a local the intravenous formulation should be used anaesthetic. Bronchospasm is not uncommon and not the oral elixir. and may be of delayed onset -that is, after
In the domiciliary setting the problems of repeated doses. The patient and his/her family preparation of the nebuliser solution (use of must be warned of this potential complication controlled drugs in glass vials, need to mix with and the first dose should be given in a su-saline) should not be underestimated. Diffipervised setting where medical or nursing inter-culties may arise if patients travel on holiday vention is available if necessary. The treatment (especially abroad) and need to take a nebuliser should be reviewed regularly. In asthmatic and opioid ampoules -a letter of authorisation patients it may be useful to prescribe a broncho-should be given and an adequate supply disdilator routinely before treatment.
pensed before departure.
Further research  
Nebulised opioids are used to improve patient There are several areas where our knowledge about nebuliser usage in palliative care is weak care but only one paper has been published to support the use of nebulised morphine in or altogether lacking. It is cause for concern that many teams and units worldwide are using breathless patients with COPD 7 and these findings were not substantiated in two sub-nebuliser therapy increasingly, and possibly uncritically, while the evidence for benefit from the sequent studies. 
